Incannex cancels 172M Series A warrants, eliminating up to 347.2M shares from dilution

Incannex Healthcare Inc.

Agreement to cancel remaining 172M Series A warrants; cancellation payment up to $12.2M.
Combined with earlier cancellation (175.2M), total elimination of up to 347.2M potential shares.
Move ahead of Phase 2 RePOSA trial data for IHL-42X in sleep apnea expected July 2025.
CEO Joel Latham cites strengthening capital structure and proactive dilution management.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.